{"product_id":"9926hk-business-model-canvas","title":"Akeso, Inc. (9926.HK): Canvas Business Model","description":"\u003cp\u003eAkeso, Inc. stands at the forefront of healthcare innovation, redefining the landscape with its robust Business Model Canvas. By leveraging strong partnerships, cutting-edge research, and a commitment to personalized patient care, Akeso crafts unique value propositions that resonate across various customer segments. Curious about how these elements interconnect to drive business success? Read on to explore the intricate framework that powers Akeso's operations and revenue generation.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc. has strategically formed a range of key partnerships to enhance its operational capabilities and market reach, essential for achieving its objectives in the biopharmaceutical industry. These partnerships span across various segments, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\n\u003cp\u003eCollaboration with large pharmaceutical firms enables Akeso to leverage their extensive distribution networks and market research capabilities. In 2022, Akeso entered into a partnership with \u003cstrong\u003eAmgen Inc.\u003c\/strong\u003e for the development of bispecific antibodies, aiming to enhance treatment efficacy for cancer patients. This partnership not only strengthens Akeso's R\u0026amp;D portfolio but also positions it to tap into Amgen's established market presence.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnerships\u003c\/th\u003e\n        \u003cth\u003eType\u003c\/th\u003e\n        \u003cth\u003eYear Initiated\u003c\/th\u003e\n        \u003cth\u003eFocus Area\u003c\/th\u003e\n        \u003cth\u003eProjected Value (USD)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAkeso - Amgen\u003c\/td\u003e\n        \u003ctd\u003eCollaborative Research\u003c\/td\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003eBispecific Antibodies\u003c\/td\u003e\n        \u003ctd\u003e500 Million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAkeso - AbbVie\u003c\/td\u003e\n        \u003ctd\u003eCo-development\u003c\/td\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003eImmuno-oncology\u003c\/td\u003e\n        \u003ctd\u003e300 Million\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eMedical Device Manufacturers\u003c\/h3\u003e\n\n\u003cp\u003eAkeso collaborates with medical device manufacturers to integrate its therapeutics with innovative medical technology. A significant partnership with \u003cstrong\u003eMedtronic\u003c\/strong\u003e was established to develop solutions that combine drug delivery with advanced device capabilities. This collaboration is expected to enhance patient outcomes and expand market access.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\n\u003cp\u003eEngagements with healthcare providers, such as major hospitals and clinics, are pivotal for Akeso to ensure proper deployment of its products. In 2022, Akeso partnered with \u003cstrong\u003eHCA Healthcare\u003c\/strong\u003e, gaining access to a network of over 2,000 care sites in the U.S. This collaboration aids in clinical trials and real-world evidence generation for its drug pipeline.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\n\u003cp\u003eResearch partnerships are fundamental to Akeso’s innovation strategy. Collaborating with institutions like \u003cstrong\u003eJohns Hopkins University\u003c\/strong\u003e allows Akeso to access cutting-edge research and development resources. Akeso’s partnership with Johns Hopkins, established in 2020, focuses on advancing treatments for autoimmune diseases and has received funding of approximately \u003cstrong\u003e75 Million USD\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eInstitution\u003c\/th\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eYear Started\u003c\/th\u003e\n        \u003cth\u003eFocus Area\u003c\/th\u003e\n        \u003cth\u003eFunding (USD)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eJohns Hopkins University\u003c\/td\u003e\n        \u003ctd\u003eResearch Collaboration\u003c\/td\u003e\n        \u003ctd\u003e2020\u003c\/td\u003e\n        \u003ctd\u003eAutoimmune Diseases\u003c\/td\u003e\n        \u003ctd\u003e75 Million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eStanford University\u003c\/td\u003e\n        \u003ctd\u003eClinical Trials\u003c\/td\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003eCancer Research\u003c\/td\u003e\n        \u003ctd\u003e50 Million\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese key partnerships are vital for Akeso as they not only enable the company to mitigate risks associated with R\u0026amp;D and market entry but also enhance its capability to offer comprehensive healthcare solutions that integrate both therapeutics and advanced medical technology.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc. is a biopharmaceutical company focused on research and development of innovative therapies. Its key activities are vital for delivering its value proposition effectively. The following sections delineate these critical actions.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\n\u003cp\u003eR\u0026amp;D is a cornerstone of Akeso's operations. In 2022, the company reported an expenditure of approximately \u003cstrong\u003e$126 million\u003c\/strong\u003e on R\u0026amp;D activities. This investment supports the advancement of its pipeline, which includes over \u003cstrong\u003e10 drug candidates\u003c\/strong\u003e in various developmental stages, primarily focusing on oncology and autoimmune diseases. Akeso's lead product, \u003cstrong\u003eAkeso-ICD\u003c\/strong\u003e, has shown promising results in early-phase trials.\u003c\/p\u003e\n\n\u003ch3\u003eClinical Trials\u003c\/h3\u003e\n\n\u003cp\u003eClinical trials are essential for regulatory approval and market entry. As of 2023, Akeso has conducted multiple Phase I, II, and III trials. Notable studies include:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003e\n\u003cstrong\u003ePhase II trial for AK102:\u003c\/strong\u003e Resulted in a \u003cstrong\u003e43.5%\u003c\/strong\u003e overall response rate among participants.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003ePhase III trial for AK105:\u003c\/strong\u003e Enrolled over \u003cstrong\u003e500 patients\u003c\/strong\u003e across several countries, with results expected in the upcoming quarters.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe average cost of a Phase III clinical trial in oncology can reach up to \u003cstrong\u003e$15 million\u003c\/strong\u003e, driving significant financial commitment from Akeso.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Medical Devices\u003c\/h3\u003e\n\n\u003cp\u003eAkeso also engages in the manufacturing of medical devices, particularly those used in conjunction with its drug delivery systems. In 2022, the company reported manufacturing-related expenses of around \u003cstrong\u003e$40 million\u003c\/strong\u003e. Akeso employs advanced technologies to enhance production efficiency and ensure compliance with \u003cstrong\u003eGood Manufacturing Practices (GMP)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eManufacturing Expenses (in million USD)\u003c\/th\u003e\n        \u003cth\u003eProduction Output (Units)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$30\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$40\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023 (Estimate)\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$50\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e250,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eSales and Marketing\u003c\/h3\u003e\n\n\u003cp\u003eSales and marketing activities are crucial for market penetration and brand recognition. In 2022, Akeso allocated approximately \u003cstrong\u003e$35 million\u003c\/strong\u003e to these efforts. The company utilizes a multi-channel approach, targeting healthcare professionals and institutions. Key activities include:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eParticipating in over \u003cstrong\u003e25 industry conferences\u003c\/strong\u003e annually.\u003c\/li\u003e\n    \u003cli\u003eEngaging in digital marketing campaigns aimed at increasing awareness of its product offerings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAkeso's sales team consists of around \u003cstrong\u003e200 professionals\u003c\/strong\u003e, focusing on building relationships with key stakeholders in the healthcare sector.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc. relies on several key resources which are vital for its operations and ability to deliver value to customers.\u003c\/p\u003e\n\n\u003ch3\u003ePatented Technologies\u003c\/h3\u003e\n\u003cp\u003eAkeso has developed a robust portfolio of patented technologies. As of October 2023, the company holds more than \u003cstrong\u003e40 patents\u003c\/strong\u003e in the fields of monoclonal antibodies and biopharmaceuticals. These patents are pivotal in providing a competitive edge in drug development, particularly in oncology and autoimmune diseases.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Medical Researchers\u003c\/h3\u003e\n\u003cp\u003eHuman capital is a critical resource for Akeso. The company employs over \u003cstrong\u003e300 highly skilled researchers\u003c\/strong\u003e, many of whom have advanced degrees in fields such as biology, chemistry, and pharmacology. This expertise is reflected in the company's R\u0026amp;D expenditures, which amounted to approximately \u003cstrong\u003eRMB 1.3 billion\u003c\/strong\u003e in 2022, representing around \u003cstrong\u003e35% of total revenue\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eAkeso's manufacturing capabilities are also a significant resource. The company has invested heavily in its facilities, with a state-of-the-art manufacturing plant located in \u003cstrong\u003eZhuhai, China\u003c\/strong\u003e. This facility is capable of producing \u003cstrong\u003eup to 200 liters\u003c\/strong\u003e of biopharmaceuticals per batch. The operational capacity of the facility supports the recent approval for large-scale production of Akeso’s key drug, \u003cstrong\u003eAK104\u003c\/strong\u003e, which is designed for the treatment of various cancers.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eResource Type\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eCurrent Status\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatented Technologies\u003c\/td\u003e\n        \u003ctd\u003eTotal patents held\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40+\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Medical Researchers\u003c\/td\u003e\n        \u003ctd\u003eNumber of researchers employed\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300+\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eLocation and capacity\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003eZhuhai, China - Up to 200 liters per batch\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenditure\u003c\/td\u003e\n        \u003ctd\u003eTotal R\u0026amp;D spending in 2022\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003eRMB 1.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eStrategic Alliances\u003c\/h3\u003e\n\u003cp\u003eAkeso has formed strategic alliances with several leading pharmaceutical companies and research institutions. In 2023, the company entered a collaboration agreement with \u003cstrong\u003eAmgen\u003c\/strong\u003e to develop combination therapies, which is expected to enhance the efficacy of Akeso’s products. These alliances not only offer access to additional resources but also broaden the market reach of Akeso’s innovations.\u003c\/p\u003e \n\n\u003cp\u003eAdditionally, Akeso's partnership with global contract research organizations (CROs) enables the company to expedite clinical trial processes. Such collaborations have proven fruitful, evidenced by the company’s ability to advance its pipeline, which includes \u003cstrong\u003e8 clinical-stage candidates\u003c\/strong\u003e by the end of 2023.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eAkeso, Inc.\u003c\/strong\u003e, a biotechnology company specializing in innovative health solutions, has carved a niche within the biopharmaceutical industry through various unique value propositions. These propositions cater to specific customer segments, primarily focusing on healthcare providers and patients in need of advanced medical treatments.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative Health Solutions\u003c\/h3\u003e\n\u003cp\u003eAkeso is renowned for its innovative approach, particularly in oncology, where it has developed a range of monoclonal antibody products. One of its standout products, \u003cstrong\u003eAkesobart (AK104)\u003c\/strong\u003e, is designed to target PD-1 and has shown promising results in clinical trials. As of October 2023, Akeso has reported a revenue increase of \u003cstrong\u003e42%\u003c\/strong\u003e year-over-year, driven by the successful launch and commercialization of its products.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-Quality Medical Devices\u003c\/h3\u003e\n\u003cp\u003eThe company prioritizes the development of high-quality medical devices that meet rigorous international standards. Akeso’s commitment to quality has led to its products receiving FDA approval, enabling them to capture market share in both domestic and international arenas. Notably, Akeso's recent product line expansions aim to enhance treatment efficacy, with an estimated \u003cstrong\u003e20%\u003c\/strong\u003e market penetration in the Asia-Pacific region as reported in their quarterly earnings.\u003c\/p\u003e\n\n\u003ch3\u003eCustomized Patient Care\u003c\/h3\u003e\n\u003cp\u003eAkeso understands that personalized medicine is imperative for effective treatment. The company offers customized care plans, tailoring therapies to individual patient profiles. This approach has resulted in improved patient outcomes, with clinical data indicating a \u003cstrong\u003e30%\u003c\/strong\u003e increase in treatment satisfaction rates among patients using Akeso’s therapies. Their engagement strategies further enhance patient adherence to treatment regimens, fostering long-term customer loyalty.\u003c\/p\u003e\n\n\u003ch3\u003eCutting-Edge Research\u003c\/h3\u003e\n\u003cp\u003eWith a strong emphasis on research and development, Akeso allocates a significant portion of its revenue towards R\u0026amp;D. In 2023, Akeso reported R\u0026amp;D expenditures of over \u003cstrong\u003e$100 million\u003c\/strong\u003e, reflecting its commitment to advancing drug candidates and enhancing existing therapies. The company currently has over \u003cstrong\u003e10\u003c\/strong\u003e clinical projects in progress, with several expected to enter pivotal clinical trials by late 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eValue Proposition\u003c\/th\u003e\n    \u003cth\u003eSpecific Offer\u003c\/th\u003e\n    \u003cth\u003ePerformance Indicator\u003c\/th\u003e\n    \u003cth\u003eMarket Impact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInnovative Health Solutions\u003c\/td\u003e\n    \u003ctd\u003eAkesobart (AK104)\u003c\/td\u003e\n    \u003ctd\u003eRevenue growth of \u003cstrong\u003e42%\u003c\/strong\u003e YoY\u003c\/td\u003e\n    \u003ctd\u003eIncreased market presence in oncology\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHigh-Quality Medical Devices\u003c\/td\u003e\n    \u003ctd\u003eFDA approved products\u003c\/td\u003e\n    \u003ctd\u003eMarket penetration of \u003cstrong\u003e20%\u003c\/strong\u003e in Asia-Pacific\u003c\/td\u003e\n    \u003ctd\u003eEnhanced competitive edge\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCustomized Patient Care\u003c\/td\u003e\n    \u003ctd\u003ePersonalized therapy plans\u003c\/td\u003e\n    \u003ctd\u003eTreatment satisfaction increased by \u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eImproved patient adherence\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCutting-Edge Research\u003c\/td\u003e\n    \u003ctd\u003eR\u0026amp;D expenditures over \u003cstrong\u003e$100 million\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eOver \u003cstrong\u003e10\u003c\/strong\u003e clinical projects ongoing\u003c\/td\u003e\n    \u003ctd\u003eStrong pipeline for future growth\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese value propositions illustrate Akeso’s strategic focus on innovation, quality, and patient-centric solutions, positioning the company favorably in a competitive market landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc. maintains a diverse approach to customer relationships, aiming to optimize interactions that drive customer acquisition, retention, and revenue growth. Below are the key components of their strategy:\u003c\/p\u003e\n\n\u003ch3\u003ePersonalized Support\u003c\/h3\u003e\n\u003cp\u003eAkeso leverages personalized support to enhance customer experience, especially concerning its biopharmaceutical products. In 2022, the company reported that approximately \u003cstrong\u003e75%\u003c\/strong\u003e of customer inquiries were addressed by specialized support teams, reflecting a commitment to tailored customer interactions. This personalized support is critical in the clinical trial phases where detailed product information is essential.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Account Managers\u003c\/h3\u003e\n\u003cp\u003eTo ensure a focused approach for key clients, Akeso assigns dedicated account managers. As of Q3 2023, the company employed over \u003cstrong\u003e20\u003c\/strong\u003e account managers tasked with maintaining relationships with pharmaceutical partners and healthcare professionals. This strategy has resulted in a \u003cstrong\u003e30%\u003c\/strong\u003e increase in customer satisfaction ratings as measured in their annual client feedback surveys.\u003c\/p\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\u003cp\u003eAkeso has developed loyalty programs aimed at healthcare providers and distributors. The rewards structure is designed to incentivize continued engagement with Akeso's products. In 2023, it was reported that participation in these loyalty programs resulted in a \u003cstrong\u003e15%\u003c\/strong\u003e increase in repeat orders among participating clients.\u003c\/p\u003e\n\n\u003ch3\u003eFeedback Loops\u003c\/h3\u003e\n\u003cp\u003eThe company utilizes robust feedback loops to gather insights from customers. As part of their strategy, Akeso collects and analyzes feedback quarterly, with an average response rate of \u003cstrong\u003e65%\u003c\/strong\u003e. This feedback is then integrated into product development and customer service enhancements, significantly influencing strategic planning and operational adjustments.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Interaction Type\u003c\/th\u003e\n    \u003cth\u003e2023 Participation\/Response Rate\u003c\/th\u003e\n    \u003cth\u003eImpact on Revenue (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePersonalized Support\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDedicated Account Managers\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e30%\u003c\/strong\u003e satisfaction increase\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e increase in repeat orders\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFeedback Loops\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e65%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these strategies, Akeso aims to build strong, lasting relationships with its customers, enhancing both customer loyalty and financial performance in the competitive biopharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc. utilizes a multi-faceted approach to reach its customers and effectively deliver its value proposition. The channels through which Akeso communicates with and delivers its offerings include\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMedical conferences\u003c\/li\u003e\n\u003cli\u003eOnline platforms\u003c\/li\u003e\n\u003cli\u003eDirect sales force\u003c\/li\u003e\n\u003cli\u003eHealthcare distributors\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMedical Conferences\u003c\/h3\u003e\n\u003cp\u003eAkeso participates in various medical conferences and industry events to showcase its innovative therapies and build relationships with healthcare professionals. In 2022, the company attended over \u003cstrong\u003e15\u003c\/strong\u003e major medical conferences globally, including the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress. These events provided a platform to present data on their lead products, including \u003cstrong\u003eAC001\u003c\/strong\u003e, an anti-PD-1 monoclonal antibody.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eThe company leverages online platforms to disseminate information regarding its products and research initiatives. With a growing digital presence, Akeso’s website saw over \u003cstrong\u003e1 million\u003c\/strong\u003e visits in 2022. The company also utilizes social media platforms and industry-specific online forums to enhance visibility and engage with stakeholders, obtaining an average engagement rate of \u003cstrong\u003e3.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eAkeso employs a dedicated direct sales force to establish and maintain relationships with healthcare providers. As of 2023, the company has assembled a sales team of approximately \u003cstrong\u003e200\u003c\/strong\u003e professionals. The direct sales team generated revenue of approximately \u003cstrong\u003e$50 million\u003c\/strong\u003e in 2022, accounting for \u003cstrong\u003e30%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Distributors\u003c\/h3\u003e\n\u003cp\u003ePartnerships with healthcare distributors are critical for Akeso’s market reach. The company collaborates with over \u003cstrong\u003e30\u003c\/strong\u003e healthcare distributors, enabling access to a broader network of patients and healthcare professionals. In 2022, revenue from distributor sales reached approximately \u003cstrong\u003e$70 million\u003c\/strong\u003e, representing \u003cstrong\u003e40%\u003c\/strong\u003e of Akeso's overall revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel Type\u003c\/th\u003e\n\u003cth\u003eRevenue Contribution (2022)\u003c\/th\u003e\n\u003cth\u003eKey Metrics\u003c\/th\u003e\n\u003cth\u003eNumber of Partnerships\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Conferences\u003c\/td\u003e\n\u003ctd\u003e$10 million\u003c\/td\u003e\n\u003ctd\u003e15 Conferences Attended\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline Platforms\u003c\/td\u003e\n\u003ctd\u003e$15 million\u003c\/td\u003e\n\u003ctd\u003e1 million website visits\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n\u003ctd\u003e$50 million\u003c\/td\u003e\n\u003ctd\u003e200 Sales Professionals\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Distributors\u003c\/td\u003e\n\u003ctd\u003e$70 million\u003c\/td\u003e\n\u003ctd\u003e30 Distributors\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc. operates across various customer segments, targeting specific groups to optimize its market reach and effectiveness. The following are the primary customer segments the company focuses on:\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eAkeso engages with hospitals and clinics for the distribution of its biopharmaceutical products. In 2022, the global market for hospital pharmaceuticals was valued at approximately \u003cstrong\u003e$368 billion\u003c\/strong\u003e, highlighting the substantial revenue opportunities. The number of hospitals in China alone is over \u003cstrong\u003e30,000\u003c\/strong\u003e, with over \u003cstrong\u003e1 million\u003c\/strong\u003e beds available. This segment is crucial as it acts as a significant distribution channel for Akeso's therapies.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Practitioners\u003c\/h3\u003e\n\u003cp\u003eHealthcare practitioners such as doctors and specialists are key stakeholders in prescribing Akeso's treatments. In 2023, there were about \u003cstrong\u003e3.5 million\u003c\/strong\u003e licensed medical practitioners in the United States, influencing the prescription market. The company aims to maintain strong relationships with these practitioners through continuous education and research partnerships, enabling them to better understand the clinical applications of Akeso’s products.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003eCollaborations with other pharmaceutical companies allow Akeso to leverage shared resources and expand its product offerings. In 2022, the global pharmaceutical market reached approximately \u003cstrong\u003e$1.48 trillion\u003c\/strong\u003e, with significant growth expected in emerging markets. Akeso's strategic partnerships drive innovation and accelerate the development of novel therapies, which can also enhance their market reach.\u003c\/p\u003e\n\n\u003ch3\u003ePatients with Chronic Conditions\u003c\/h3\u003e\n\u003cp\u003ePatients suffering from chronic conditions represent a critical customer segment for Akeso. As of 2021, it was estimated that over \u003cstrong\u003e133 million\u003c\/strong\u003e Americans live with chronic diseases, underscoring the need for effective treatments. Akeso's therapies, particularly in oncology and autoimmune diseases, aim to improve patients' quality of life and treatment outcomes. The chronic disease management market is projected to grow to \u003cstrong\u003e$21.5 billion\u003c\/strong\u003e by 2027, reflecting the increasing demand for these specialized treatments.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eKey Statistics\u003c\/th\u003e\n        \u003cth\u003eMarket Value\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e30,000+ hospitals in China, 1 million beds\u003c\/td\u003e\n        \u003ctd\u003e$368 billion (global hospital pharmaceuticals market)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Practitioners\u003c\/td\u003e\n        \u003ctd\u003e3.5 million licensed practitioners in the U.S.\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n        \u003ctd\u003e$1.48 trillion (global pharmaceutical market)\u003c\/td\u003e\n        \u003ctd\u003e$1.48 trillion (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatients with Chronic Conditions\u003c\/td\u003e\n        \u003ctd\u003e133 million+ Americans with chronic diseases\u003c\/td\u003e\n        \u003ctd\u003e$21.5 billion (projected by 2027)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese customer segments are integral to Akeso's business strategy, allowing for targeted marketing and tailored value propositions that meet the specific needs of each group.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eAkeso, Inc., a biopharmaceutical company, incurs various costs essential to its operations. The structure of these costs plays a significant role in its financial health and ability to sustain its business model.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\n\u003cp\u003eIn 2022, Akeso reported research and development (R\u0026amp;D) expenses of approximately \u003cstrong\u003e$177 million\u003c\/strong\u003e. This expenditure accounted for a significant portion of the company’s overall costs, reflecting its commitment to developing innovative therapeutics, particularly in oncology and autoimmune diseases.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\n\u003cp\u003eThe manufacturing costs for Akeso, including the production of their biologics, are substantial. For the year ended December 31, 2022, manufacturing costs were estimated at about \u003cstrong\u003e$62 million\u003c\/strong\u003e. This figure encompasses raw materials, facility costs, and labor associated with the manufacturing of their drug candidates.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Sales Expenses\u003c\/h3\u003e\n\n\u003cp\u003eAkeso’s marketing and sales expenses were approximately \u003cstrong\u003e$43 million\u003c\/strong\u003e in 2022. This amount reflects investments in market access strategies, promotional activities, and sales force expansion as the company prepares for potential product launches.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\n\u003cp\u003eRegulatory compliance costs are also a significant component of Akeso's cost structure. Total compliance-related expenses in 2022 reached about \u003cstrong\u003e$12 million\u003c\/strong\u003e. These costs include fees associated with regulatory submissions, monitoring, and ongoing compliance with health authority standards.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003e2022 Amount (in million USD)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e177\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e62\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Sales Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e43\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eTotal Costs\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e294\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThe total costs incurred by Akeso, Inc. for the year amounted to \u003cstrong\u003e$294 million\u003c\/strong\u003e. Efficient management of these costs is crucial for enhancing profitability and facilitating further growth opportunities in its pipeline of therapeutic candidates.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eAkeso, Inc. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eAkeso, Inc. is primarily engaged in the research, development, and commercialization of innovative biologics for the treatment of cancer and autoimmune diseases. In the fiscal year 2022, Akeso reported total revenue of approximately \u003cstrong\u003e$113 million\u003c\/strong\u003e, with product sales contributing significantly to this figure. Their key product, AK105, is in various stages of development, showing strong market potential. The revenue from product sales has demonstrated year-on-year growth, reflecting their successful market penetration and increasing demand.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Patents\u003c\/h3\u003e\n\u003cp\u003eIn addition to product sales, licensing agreements play a critical role in Akeso's revenue model. As of Q3 2023, the company has secured multiple licensing deals, including a notable partnership with AbbVie for the commercialization of AK104 outside of China. This licensing deal is projected to generate royalties that could account for up to \u003cstrong\u003e20%\u003c\/strong\u003e of sales from the licensed products. In 2022 alone, Akeso reported licensing revenue of around \u003cstrong\u003e$28 million\u003c\/strong\u003e, showcasing the financial impact of their intellectual property strategies.\u003c\/p\u003e\n\n\u003ch3\u003eService Contracts\u003c\/h3\u003e\n\u003cp\u003eAkeso has also engaged in service contracts, providing research and development services to partners and collaborators. In 2022, the revenue from these service contracts amounted to approximately \u003cstrong\u003e$15 million\u003c\/strong\u003e. The company collaborates with various pharmaceutical firms, utilizing its expertise in biologics to enhance product development timelines and efficiency. These contracts not only generate revenue but also solidify strategic partnerships within the industry.\u003c\/p\u003e\n\n\u003ch3\u003eConsulting Fees\u003c\/h3\u003e\n\u003cp\u003eConsulting services add another layer to Akeso's revenue streams. The company offers consulting on drug development and regulatory strategies, allowing other firms to benefit from their extensive experience. In the fiscal year 2022, consulting fees contributed around \u003cstrong\u003e$5 million\u003c\/strong\u003e to overall revenue. These fees primarily arise from advisory roles in navigating complex regulatory landscapes associated with biologic therapies, which are critical for market entry and compliance.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eRevenue Stream\u003c\/th\u003e\n            \u003cth\u003e2022 Revenue ($ Million)\u003c\/th\u003e\n            \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eProduct Sales\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e113\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e61.8\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eLicensing Patents\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e28\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e24.8\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eService Contracts\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e13.3\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eConsulting Fees\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e4.4\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45734812942485,"sku":"9926hk-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/9926hk-business-model-canvas.png?v=1739157931","url":"https:\/\/dcf-model.com\/products\/9926hk-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}